Brivudine - RESprotect

Drug Profile

Brivudine - RESprotect

Alternative Names: RP-101

Latest Information Update: 10 Feb 2016

Price : $50

At a glance

  • Originator RESprotect
  • Class Adjuvants; Antivirals; Deoxyribonucleosides; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Apoptosis stimulants; DNA-directed DNA polymerase inhibitors; Genetic transcription inhibitors; HSP27 heat shock protein inhibitors; STAT3 transcription factor inhibitors; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III Pancreatic cancer
  • Phase I Solid tumours
  • Preclinical Infections

Most Recent Events

  • 08 Feb 2016 RedHill Biopharma and Fraunhofer Institute for Cell therapy and Immunology agree to co-develop brivudine for Solid tumours
  • 15 Jun 2015 No recent reports of development identified - Phase-II for Pancreatic cancer in South America (PO)
  • 15 Jun 2015 Phase II/III development for Pancreatic cancer is ongoing in Europe and the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top